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Abstract
Background The latest studies on surgical and cost-analysis outcomes after laparoscopic distal pancreatectomy (LDP) highlight
mixed and insufficient results. Whereas several investigators have compared surgical outcomes of LDP vs. open distal pancre-
atectomy (ODP) for adenocarcinomas, few similar studies have focused on pancreatic neuroendocrine tumors (PNETs).
Methods We reviewed the medical records of PNET patients undergoing distal pancreatectomy between 2004 and 2014. Patients
were divided into LDP vs. ODP groups. Demographics, relevant comorbidities, oncologic variables, and cost-analysis data were
assessed. Survival and Cox proportional hazards analyses were used to evaluate outcomes.
Results Of the 171 distal pancreatectomies for PNETs, 73 were laparoscopic, whereas 98 were open. Patients undergoing LDP
demonstrated significantly lower rates of postoperative complications (P=0.028) and had significantly shorter hospital stays (P=
0.008). On multivariable analysis, positive resection margins (P=0.046), G3 grade (P=0.036), advanced WHO classification
(P=0.016), TNM stage (P=0.018), and readmission (P=0.019) were significantly associated with poor survival; however,
method of resection (LDP vs. ODP) was not (P=0.254). Themedian total direct costs of LDP vs. ODP did not differ significantly.
Conclusions In response to the recent considerable controversy surrounding the costs and surgical outcomes of LDP vs. ODP,
our results show that LDP for PNETs is cost-neutral and significantly reduces postoperative morbidity without compromising
oncologic outcomes and survival.
Keywords Pancreatic neuroendocrine tumors . Distal
pancreatectomy . Laparoscopic pancreatectomy
Introduction
Pancreatic neuroendocrine tumors (PNETs) are rare,
representing approximately 2–4 % of all pancreatic tumors
with an incidence of 2–3 cases per million people.1,2 In
contrast to pancreatic adenocarcinoma, PNETs encompass a
wider biological spectrum, which grants them a poorly de-
fined natural history and often a challenging prognosis.3,4
Surgery is the standard curative modality for PNETs; howev-
er, surgical and oncologic outcomes vary significantly de-
pending on whether the tumor is single or multiple, benign
or malignant, functioning or nonfunctioning or whether re-
sectable metastatic disease to the liver is present.3–5
Laparoscopic distal pancreatectomy (LDP) is well suited for
complete radical resection of PNETs located in the pancreatic
body or tail, at least for tumors that are relatively small and
solitary.
Compared to open distal pancreatectomy (ODP), LDP per-
formed in well-selected groups of pancreatic lesions has been
confirmed to have superior results in terms of intraoperative
blood loss, postoperative pain, time to recovery, and length of
hospital stay (LHS).6–9 Despite these findings, latest reports
on surgical outcomes of LDP vs. ODP highlight relevant in-
consistencies between the two techniques. These inconsis-
tencies involve operating time, rates of postoperative
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complications, pancreatic fistula, spleen preservation and con-
version, costs, but more importantly, oncologic outcomes.10,11
Several investigators claim that the results of the surgical
outcomes of LDP, as opposed to ODP, are neither clearly
demonstrated nor generalizable due to underpowered existing
comparative studies, introduction of important selection
biases, and the nationwide underuse of laparoscopic
pancreatectomy.12–14 Additionally, little data exist on long-
term oncologic outcomes and mortality rates between LDP
vs. ODP; therefore, studies with larger sample sizes and longer
follow-ups are needed to clarify these issues.10,11 In an era of
limited resources, concerns have been also raised about in-
creasing costs for the laparoscopic approach, due to prolonged
operating time and the relatively high cost of disposable sur-
gical devices.15
Many reports on surgical outcomes after LDP vs. ODP
have focused exclusively on well-selected subsets of pancre-
atic lesions to ensure homogeneous sampling, especially giv-
en that tumor factors may affect a patient’s suitability for lap-
aroscopic resection.16,17 These comparative cohorts have pre-
dominately analyzed LDP vs. ODP outcomes for pancreatic
adenocarcinoma. Few large series have assessed similar out-
comes for PNETs due to their heterogeneity and complex
patterns of clinical behavior, which cause significant variabil-
ity in oncologic outcomes and survival.4,5,18 To clarify mixed
findings and to address recent salient controversies regarding
postoperative, oncologic, and cost-analysis outcomes after
LDP vs. ODP, we focused on a subset of PNET patients
who underwent distal pancreatectomy at our institution.
Materials and Methods
The study was approved by our Institutional Review Board
(IRB). International Classification of Disease (ICD)-9 codes
for PNETs were identified from the Research Patient Data
Registry (RPDR). A selected subset of patients with surgically
resected, pathologically confirmed PNETs between July 2004
and 2014 were identified. After initial review of medical re-
cords, we excluded from the final analysis patients with mul-
tiple endocrine neoplasia type I or Von Hippel–Lindau dis-
ease, given their association with multiple other neoplasms
that require more than pancreatic resection for cure.
Descriptive data were collected by review of patient’s med-
ical records. Preoperative variables included age, gender, race,
and relevant comorbidities, such as history of smoking, alco-
hol use, and diabetes mellitus. Patients with signs, symptoms,
and biochemical evidence of pancreatic hormonal excess were
considered to have functioning tumors, which were histopath-
ologically confirmed after resection, whereas patients with no
recognizable clinical syndrome and normal serum hormone
levels were considered to have nonfunctioning tumors.
Preoperative assessment of serum Chromogranin A levels
were also recorded using a cutoff range of 84–87U/L to obtain
a high specificity for PNETs.19 Operations were grouped as
LDP vs. ODP with or without spleen preservation or liver
resection.
Detailed baseline information on PNETs included tumor
diameter and location. Distant metastasis was defined as liver
metastases when only the liver was involved and liver and
extra-hepatic metastases when bone, lung, or brain metastases
were additionally demonstrated. Pathological characteristics
included tumor grade, lymphovascular invasion, regional
lymph node status, and resection margin status, which were
determined from final pathology reports. Tumors were classi-
fied according to the World Health Organization system
(WHO)20 and staged according to the TNM scheme, which
has been proposed by the European Neuroendocrine Tumor
Society (ENETS).21
Postoperative complications were gathered from daily
progress notes and discharge summaries. Postoperative pan-
creatic fistula (POPF) was assessed in 98 % of patients in this
cohort and defined as abdominal drainage with an amylase
level >3 times the upper limit of normal after postoperative
day number 3, according to the International Study Group on
Pancreatic Fistula (ISGPF) recommendations. POPFs were
additionally graded based on the ISGPF criteria as follows:
biochemical fistulas without clinical sequelae were graded as
A. Those requiring any therapeutic intervention were graded
as B, and fistulas with severe clinical sequelae were graded as
C.22 Abscess was diagnosed when culture-positive purulent
drainage from an intra-abdominal fluid collection was
obtained percutaneously or operatively and/or when fluid
collection with systemic or localized signs of infection was
confirmed radiologically. Wound infection was defined as any
wound that required opening or antibiotics beyond standard
prophylaxis.
R0 resection was considered when the primary tumor was
removed with negativemargins. Patients with microscopically
or grossly positive margins were classified as having had an
R1 or R2 resection, respectively. Conversion was defined as
the need for an abdominal incision to deal with any intraoper-
ative complication and allow completion of the case. LHSwas
calculated from date of operation to date of hospital discharge.
Readmission was defined as re-hospitalization within 30 days
from discharge. Perioperative mortality was defined as death
within 30 days from the operation, or within the original hos-
pital admission. Survival was calculated from the date of op-
eration through the date of last follow-up.
For cost-analysis purposes, standard tariffs set by our hos-
pital independent coding and costing committee were
adopted. The cost per patient visit was retrieved using record-
ed information by patient medical record number, and specific
visit number using the institution’s financial cost accounting
system. Total direct costs were defined as the median cost
across cases in each group, and included all costs associated
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with the inpatient encounter, from admission to discharge for
all hospital services provided. For both the LDP and ODP
groups, cost analysis included the following:
& Operating room (OR) time in minutes, which was defined
as the time from which the patient entered the operating
room to the time at which he exited
& OR costs including team costs driven by the duration of
the case, supplies, and recovery room costs
& Intra- and postoperative blood transfusion requirement
costs
& Nursing, pharmacy, and laboratory testing costs
& Postoperative imaging costs including radiological re-
intervention within the same hospitalization
Other costs included anesthesia, cardiac noninvasive test-
ing, emergency department costs, gastrointestinal endoscopy,
nutrition services, OR special charges, physical and occupa-
tional therapy, radiation therapy, and respiratory/pulmonary
therapy costs. Indirect costs were excluded from our
calculations.
The 11 laparoscopic cases, which were converted to open,
were classified under the LDP category according to an intent-
to-treat analysis framework. Continuous variables were
compared using Student’s t test or Wilcoxon rank-sum
test, whereas categorical variables were compared using
Pearson’s chi-squared test or Fisher’s exact test as ap-
propriate. Survival probability was estimated using the
Kaplan–Meier method and compared using the log-rank
test. Univariate and multivariable analyses were per-
formed using Cox proportional hazards models. For cost
analysis, we compared ratios of median costs for each
cost category and reported the percentage of change in
median cost. Continuous variables are reported as mean
±standard deviation or median and range. Categorical
variables are presented as numbers (n) and percentages
(%). A P value of less than 0.05 was considered statistically
significant. Statistical analyses were conducted using the SAS
statistical software program version 9.2 (SAS Institute,
Cary, NC).
Results
We compared 73 PNET patients who underwent LDP to 98
patients who underwent ODP.
Demographics and Clinical Characteristics
Demographics and clinical characteristics are described in
Table 1. The median age of the entire cohort was 61 years
(range 20–95) with 89 male (52 %) and 153 Caucasian pa-
tients (89 %). There were no statistically significant
differences with respect to age, gender, race, body mass index
(BMI), and relevant comorbidities between the two groups.
Overall, 37 patients (22 %) had functioning tumors, including
29 insulinomas, 5 gastrinomas, 2 glucagonomas, and 1 adre-
nocorticotropic hormone (ACTH)-secreting tumor, whereas
134 patients (78 %) had nonfunctioning tumors. A statistically
higher proportion of patients with functioning tumors
underwent ODP, whereas those with nonfunctioning tumors
more often underwent LDP (P=0.010).
Table 1 Demographics and clinical characteristics of PNET patients







Median age, n (range) 61 (20–95) 62 (34–92) 0.334
Male gender, n (%) 41 (56 %) 48 (49 %) 0.358
Race, n (%):
Caucasian 64 (88 %) 89 (91 %) 0.616
African American 2 (3 %) 3 (3 %) 0.901
Hispanic 2 (3 %) 1 (1 %) 0.397
Asian 5 (6 %) 5 (5 %) 0.630
Median BMI, n 27.8 28.4 0.756
History of smoking, n (%) 21 (28 %) 31 (31 %) 0.687
Alcohol use, n (%) 20 (27 %) 22 (22 %) 0.457
Diabetes, n (%) 12 (16 %) 13 (13 %) 0.561
Tumor type, n (%):
Nonfunctioning 64 (88 %) 70 (72 %) 0.010
Insulinoma 8 (11 %) 21 (21 %) 0.098
Gastrinoma 1 (1 %) 4 (4 %) 0.297
Glucagonoma 0 2 (2 %) 0.507
ACTHoma 0 1 (1 %) 0.386
Presence of signs or symptoms, n (%):
Asymptomatic 52 (72 %) 50 (51 %) 0.007
Palpitations 0 1 (1 %) 0.386
Diarrhea 0 4 (4 %) 0.080
GI ulcers 1 (1 %) 0 0.426
Migratory erythema 0 1 (1 %) 0.386
Weight gain 0 1 (1 %) 0.386
Vague abdominal pain 9 (12 %) 18 (18 %) 0.284
Weight loss 3 (4 %) 1 (1 %) 0.186
Jaundice 1 (1 %) 0 0.426
Hypoglycemia 7 (10 %) 19 (20 %) 0.077
Hyperglycemia 0 1 (1 %) 0.386
Fatigue 0 2 (2 %) 0.507
High Chromogranin A levels,
n (%)
28 (38 %) 34 (35 %) 0.622
Median lesion size, cm (range) 2.2 (0.2–13) 2.7 (0.4–15) 0.056
Location, n (%):
Body 11 (15 %) 22 (22 %) 0.226
Tail 62 (85 %) 76 (78 %) 0.246
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Overall, 69 patients (40 %) were symptomatic. A significant-
ly lower percentage of symptomatic patients underwent LDP
(28 vs. 49 %, LDP vs. ODP respectively, P=0.007). Despite
this, therewere no statistically significant differenceswith regard
to the type of symptoms between the two groups. Abdominal
pain was most frequently present in patients undergoing LDP
(12 %), whereas hypoglycemia was the most frequent symptom
occurring in patients who had ODP (20 %). Sixty-two patients
(36 %) had elevated serum Chromogranin A levels, but this was
not significantly different between patients undergoing LDP vs.
ODP (38 vs. 35 %, LDP vs. ODP, P=0.622).
Tumor Size and Location
The size and anatomic location of the resected PNETs are also
described in Table 1. The median tumor diameter in patients
undergoing LDP, as determined by pathology, was lower com-
pared to the median tumor diameter of those who had ODP
(2.2 vs. 2.7 cm, LDP vs. ODP, P=0.056). Overall, 33 PNETs
were located in the body of the pancreas (19 %), whereas 138
were located in the tail (81 %).
Operations
Overall, 171 distal pancreatectomies were performed. Fifty-
one patients undergoing LDP required a splenectomy com-
pared to 60 patients who underwent ODPs (61 vs. 69 %,
LDP vs. ODP, P=0.260). Seven patients (4 %) had a simulta-
neous liver resection, of which two were performed during
LDP, whereas five during ODP (3 vs. 5 %, LDP vs. ODP,
P=0.700). In 11 patients (15 %), a laparoscopic procedure
was converted to laparotomy: six procedures were converted
due to deep adhesions, which prevented visibility, and five
others were converted due to intraoperative bleeding that
could not be controlled laparoscopically. Although the OR
time of LDPs was shorter compared to the OR time for
ODPs, such difference was not statistically significant (352
vs. 409 min, LDP vs. ODP respectively, P=0.065).
Pathologic Characteristics
Fifty-four PNETs (74 %) of patients undergoing LDP were
low-grade, 15 intermediate-grade (20 %), and 4 high-grade
(6 %) vs. 71 low-grade (72 %), 20 intermediate-grade
(21 %), and 7 high-grade (7 %) of those undergoing ODP
(Table 2). Seventeen tumors resected with laparoscopic sur-
gery (23 %) had microscopic evidence of lymphovascular
invasion vs. 35 of those resected using the open technique
(35 %). In the LDP group, 11 patients (15 %) had positive
regional lymph nodes, and three patients (4 %) had distant
metastases at the time of resection. In contrast, in the ODP
group, 19 patients (19 %) had positive regional lymph nodes
and 11 patients (11 %) had distant metastases. Five of the 14
patients with metastatic disease (36 %) underwent resection of
their primary PNET only, whereas nine underwent synchro-
nous liver resection or cryoablation (64 %). Overall, 162 pa-
tients (95 %) had complete resection (R0), whereas nine pa-
tients (5 %) had evidence of microscopic disease on the pan-
creatic margin (R1).
According to the WHO classification, 132 patients (77 %)
had WDT (82 vs. 74 %, LDP vs. ODP, P=0.200), 28 patients
(16%) hadWDCa (12 vs. 19%, LDP vs. ODP, P=0.296), and
11 patients (6 %) had PDCa (6 vs. 7 %, LDP vs. ODP, P=
0.760). In terms of TNM stage, overall 72 patients (42 %) had
stage 1 disease, 65 patients (38 %) stage 2, 23 patients (13 %)
stage 3, and 11 patients (7 %) stage 4 disease. Although the
LDP group had more WDTs and lower stages of disease, the
two groups did not differ significantly in terms of pathologic
characteristics of their tumors (Table 2).
Postoperative and Oncologic Outcomes
The overall surgical morbidity in terms of postoperative com-
plications was 40 %. Sixteen patients (9 %) required reopera-
tion due to: incisional hernia (n=5), tumor recurrence (n=7),
necrotizing pancreatitis associated with intra-abdominal ab-
scess (n=2), small bowel obstruction (n=1), and persistent
pancreatic leak associated with hemorrhage (n=1). Twenty-
one patients (12 %) required readmission for the treatment of
postoperative complications. Overall, there was one perioper-
ative death (1.02 %) after ODP for WDCa.







Low (G1) 54 (74 %) 71 (72 %) 0.824
Intermediate (G2) 15 (20 %) 20 (21 %) 0.982
High (G3) 4 (6 %) 7 (7 %) 0.760
Lymphovascular invasion, n (%) 17 (23 %) 35 (35 %) 0.094
Positive lymph nodes, n (%) 11 (15 %) 19 (19 %) 0.426
Distant metastasis, n (%) 3 (4 %) 11 (11 %) 0.093
Positive resection margins, n (%) 2 (3 %) 7 (7 %) 0.303
WHO classification, n (%):
Well-differentiated tumor (WDT) 60 (82 %) 72 (74 %) 0.200
Well-differentiated carcinoma
(WDCa)
9 (12 %) 19 (19 %) 0.296
Poorly differentiated carcinoma
(PDCa)
4 (6 %) 7 (7 %) 0.760
TMN stage, n (%):
Stage 1 34 (47 %) 38 (39 %) 0.348
Stage 2 28 (38 %) 37 (38 %) 0.100
Stage 3 8 (11 %) 15 (15 %) 0.499
Stage 4 3 (4 %) 8 (8 %) 0.356
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For the entire cohort, the median LHS was 6 days (range of
3–39) and the median follow-up was 41 months (range of 2–
254). There were no statistically significant differences in
terms of follow-up between the two groups (32 vs. 44 months,
LDP vs. ODP, P=0.371). During this time, overall seven pa-
tients (4 %) developed recurrences. Five patients had a tumor
recurrence in the liver, whereas two patients had recurrences
in the liver and pancreatic bed. Recurrences occurred between
a minimum of 17 and 108 months. The 5-year survival for the
entire cohort was 95 %. The 5-year survival for patients with
WDT, WDCa, and PDCa was 98.4, 71.4, and 36.3 %, respec-
tively (P<0.001, Fig. 1). The 5-year survival for patients with
TNM stages 1, 2, 3, and 4 was 98.6, 95.3, 73.9, and 36.3 %,
respectively (P<0.001, Fig. 2). Type of surgery (LDP vs.
ODP) did not influence the 5-year survival (log-rank test,
P=0.254, Fig. 3).
Although the most frequent major postoperative complica-
tion in both groups was POPF, we had no statistically signif-
icant differences in terms of frequency of occurrence (22 vs.
33 %, LDP vs. ODP, P=0.168) or severity grade (grade A, 16
vs. 18 %, LDP vs. ODP, P=0.840) between the two groups
(Table 3). Despite having no significant differences with re-
spect to individual type of complications (pancreatic fistula,
incisional hernia, intra-abdominal collection, bowel obstruc-
tion, or superficial or deep would infection) between the LDP
and ODP groups, we observed statistically significant differ-
ences in the overall rates of postoperative complications: few-
er patients undergoing LDP developed postoperative compli-
cations (30 vs. 47 %, LDP vs. ODP, P=0.028, Table 3).
Additionally, for the entire cohort, we had no statistically
significant differences between the two groups in terms of
readmission rates (12 vs. 19 %, LDP vs. ODP, P=0.296) or
reoperation (8 vs. 10 %, LDP vs. ODP, P=0.659). There were
no perioperative deaths in the LDP group, but there was one
death (1.02 %) in the ODP group (P=0.386). Patients who
underwent LDP had a significantly shorter median LHS than
those undergoing ODP [5 days (range of 3–18) vs. 7 days
(range of 4–39), LDP vs. ODP, P=0.008]. With a median
follow-up of 32 months (range of 3–185), three patients
in the LDP group (4 %) developed a recurrence. Similarly,
with a median follow-up of 44 months (range of 2–254), four
patients in the ODP group (4 %) developed recurrences
(P=0.992). During follow-up, four patients (5 %) in the
LDP group died vs. 13 patients (13 %) in the ODP group
(P=0.122), (Table 3).
Potential Predictors of Poor Survival in Patients with PNETs
Additionally, we performed an analysis of potential prognostic
factors impacting survival after distal pancreatic resection for
PNETs. On univariate analysis (Table 4), tumor size >3 cm
(P=0.041) and positive resection margins (P=0.016) predict-
ed poor survival. Furthermore, tumor grade G-3 vs. G-1
(P=0.041), WDCa (P=0.003) and PDCa (P<0.001) vs.
WDT by WHO classification, and stages 3 (P=0.014) and 4
(P<0.001) vs. stage 1 by TMN, were also significantly
associated with poor survival. In contrast, age >60 years
(P=0.231), male gender (P=0.223), Caucasian race (P=
0.983), presence of symptoms (P=0.937), functioning tumor
type (P=0.954), tumor location (either body or tail, P=0.839),
type of resection (LDP vs. ODP, P=0.479), presence of post-
operative complications (P=0.390), readmission (P=0.491),
reoperation (P=0.689), and recurrence (P=0.996) did not cor-
relate with poor survival.
Fig. 1 Kaplan–Meier estimates
of survival for patients who
underwent R0/R1 distal resection
for PNETs. Five-year survival
estimates stratified by WHO
classification for patients with
WDT, WDCa, and PDCa were
98.4, 71.4, and 36.3 %,
respectively (log-rank test,
P<0.001)
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On multivariable analysis when controlling for demo-
graphics and clinical characteristics—including age, gender,
presence of symptoms, and functioning tumor type—positive
resection margins (P=0.046), tumor grade G-3 (P=0.036),
poorly differentiated tumors [WDCa (P=0.002) and PDCa
(P=0.016)], TNM stage 3 (P=0.032), TNM stage 4 (P=
0.018), and readmission (P=0.019) remained significantly as-
sociated with poor survival (Table 5). On multivariable anal-
ysis, tumor >3 cmwas no longer associated with poor survival
(P=0.475).
Case Costing
Complete data from 123 PNET patients—56 who underwent
LDP and 67 who underwent ODP— were available for anal-
ysis. The breakdown of the operative and hospital costs are
described in Table 6. The LDP and ODP cohorts did not differ
significantly in terms of median ORminutes (352 vs. 409 min,
LDP vs. ODP, P=0.065). Although the median total direct
costs for the LDP group were 20 % lower, compared to the
ODP group, this was not statistically significant (P=0.179).
Fig. 2 Five-year survival
estimates stratified by ENETS-
TNM stage for patients with
stages 1, 2, 3, and 4 disease were
98.6, 95.3, 73.9, and 36.3 %,
respectively (log-rank test,
P<0.001)
Fig. 3 Kaplan–Meier estimates
of survival for patients who
underwent LDP vs. ODP for
PNETs. Type of surgery (LDP vs.
ODP) did not influence 5-year
survival (log-rank test, P=0.254)
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Similarly, the median OR costs for the LDP group were
10.5 % higher than the median OR costs for the ODP
group, but still not statistically significant (P=0.091).
Detailed analysis of OR costs revealed no statistically
significant differences in terms of recovery room costs
between the two groups (P=0.466), but median OR team
and median supply costs were respectively 20 % lower
(P=0.027) and 91.7 % higher (P<0.001) for the LDP
group. Median blood, nursing and laboratory costs were,
respectively, 24.4, 25.6, and 38.4 % lower in the LDP
group, and despite the statistical significance, this did not gen-
erate differences in the total direct costs between the
groups. The remaining hospital costs, including costs
for pharmaceuticals (P=0.154), imaging (P=0.526), and oth-
er costs (P=0.317), were not significantly different between
the two groups (Table 6).







Uncomplicated 51 (70 %) 52 (53 %) 0.028
Postoperative pancreatic fistula
(POPF)
16 (22 %) 32 (33 %) 0.168
Incisional hernia 0 5 (5 %) 0.072
Intra-abdominal collection/abscess 6 (8 %) 5 (5 %) 0.531
Bowel obstruction 0 2 (2 %) 0.507
Wound infection (superficial
or deep)
0 2 (2 %) 0.507
ISGPF pancreatic fistula, n (%):
Grade A 12 (16 %) 18 (18 %) 0.840
Grade B 4 (6 %) 12 (13 %) 0.185
Grade C 0 2 (2 %) 0.507
Readmission, n (%) 9 (12 %) 19 (19 %) 0.296
Reoperation, n (%) 6 (8 %) 10 (10 %) 0.659
Overall mortality, n (%) 4 (5 %) 13 (13 %) 0.122
Median LHS, days (range) 5 (3–18) 7 (4–39) 0.008
Median follow-up, months (range) 32 (3–185) 44 (2–254) 0.371
Recurrence, n (%) 3 (4 %) 4 (4 %) 0.992




95 % CI for
HR
P value
Age (>60) 0.556 0.213–1.454 0.231
Male 1.847 0.688–4.956 0.223
Caucasian 1.016 0.221–4.667 0.983
Presence of symptoms 0.961 0.357–2.586 0.937
Functioning tumor type 0.970 0.339–2.773 0.954
Tumor size >3 cm 4.681 1.065–20.572 0.041
Tumor location (tail) 2.805 0.366–2.477 0.839
Open surgery 1.513 0.480–4.771 0.479
High Chromogranin A levels 1.210 0.412–3.551 0.728
Positive resection margins 4.060 1.288–12.799 0.016
High-grade tumor (G3) 3.029 1.044–8.790 0.041
WDCa 10.041 2.093–48.173 0.003
PDCa 25.108 5.170–121.939 <0.001
TMN stage 3 14.642 1.693–126.591 0.014
TMN stage 4 63.680 7.286–556.531 <0.001




Readmission 1.448 0.505–4.152 0.491
Reoperation 1.291 0.368–4.529 0.689
Presence of recurrence 1.004 0.130–7.760 0.996




95 % CI for
HR
P value
Tumor size >3 cm 0.475 0.143–1.580 0.475
Positive resection margins 5.234 1.030–26.595 0.046
High-grade tumor (G3) 4.276 1.099–16.638 0.036
WDCa 13.050 2.432–70.041 0.002
PDCa 9.237 1.505–56.679 0.016
TMN stage 3 16.173 1.258–207.994 0.032
TMN stage 4 18.127 1.628–201.869 0.018
Readmission 11.860 1.522–92.398 0.019
Table 6 Breakdown of ratio and percentage change in median costs








Operating room minutes 0.84 −13.5 % 0.065
Total direct cost 0.80 −20.0 % 0.179
Operating room (OR) cost: 1.12 10.5 % 0.091
OR team 0.81 −20.0 % 0.027
Supplies 1.93 91.7 % <0.001
Recovery room 0.83 −17.2 % 0.466
Blood cost 0.75 −24.4 % 0.020
Nursing cost 0.75 −25.6 % 0.048
Pharmacy cost 0.85 −15.3 % 0.154
Laboratory cost 0.61 −38.4 % 0.002
Radiology cost 0.52 −46.2 % 0.526
Other cost 0.97 −0.65 % 0.317
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Discussion
Many recent studies have shown that laparoscopic pancreatic
surgery in well-selected groups of patients, as opposed to the
open technique, is safe and associated with various equivalent
or better surgical outcomes.5–9,23–26 However, there has been a
steadily growing debate about the small size of these studies,
the presence of significant selection biases, the lack of gener-
alizability of results and the short-term follow-ups.10–14 In this
study, we aim to put the controversy to rest on the impact of
LDP for PNETs on postoperative, oncologic, and cost-
analysis outcomes.
Few large series have compared surgical outcomes of LDP
vs. ODP for PNET patients.4,5,18 The vast majority of the
PNETs in our study were nonfunctioning (78 %), which is
consistent with other reports in the literature.18 Of the 37 pa-
tients with functioning PNETs, a significantly higher percent-
age underwent ODPs. In accordance with their functioning
tumors, patients undergoing ODP were more often symptom-
atic, with abdominal pain and hypoglycemia being the most
common presenting symptoms. Patients with smaller neo-
plasms were more frequently chosen for LDP, which is com-
monly observed in previous similar reports.5,12
With regard to intraoperative outcomes, many series have
shown that the duration of LDP is significantly longer when
compared to ODP.6,15,27–29 However, our results show no sig-
nificant differences between the duration of the two ap-
proaches. Discrepancies regarding surgical case duration
may be attributed to differences in tumor size as well as dif-
ferences regarding the various stages of disease, which may
require a more or less extensive resection. Despite not having
statistically significant differences between the LDP and ODP
groups in terms of spleen preservation, our splenectomy rates
were lower in the LDP group. Lower splenectomy rates after
LDP reached a statistical significance in recent similar com-
parative series.10,14 This might be explained by a planned
splenectomy due to higher rates of malignancy in the ODP
group; in which case, proximity of tumor to the splenic vas-
culature often makes preservation difficult. Based on the liter-
ature, conversion rates of LDP may vary significantly. In this
study, conversion rates were significantly lower compared to
other series.14,30 This might be explained by our low rate of
intraoperative complications in addition to the relative ease of
identifying PNETs without needing intraoperative ultrasound.
However, high rates of conversion highlight the demand for
specific training in LDP.
Recent studies show no significant differences in
terms of postoperative morbidity between the two
techniques.5,11,13–15,28 However, some of these studies are
not specific and include both benign and malignant pancreatic
lesions. In contrast, our data support that PNET patients un-
dergoing LDP have significantly lower rates of overall post-
operative complications, including POPF, incisional hernia,
intra-abdominal collection or abscess, bowel obstruction,
and superficial or deep wound infection. Without
reaching statistical significance, we observed that the LDP
group experienced fewer POPFs compared to the ODP group,
which is conflicting with recent results obtained by other
investigators.10,11,13,14 However, some of these reports are un-
derpowered, and others are large meta-analyses, which in-
clude studies of suboptimal quality. Moreover, in these stud-
ies, there is significant inconsistency regarding the definition
of POPF and differences between the clinical grading of
POPFs were not always assessed. Therefore, the real advan-
tage of LDP on the rates of POPF remained an open issue. Our
LDP group was also associated with less intraoperative blood
loss and had significantly shorter hospital stays when com-
pared to the ODP group. This short hospital stay favored ac-
celerated recovery and simultaneously contributed to lowering
the costs of hospitalization. Our analysis failed to demonstrate
any significant differences between the two groups with re-
gard to postoperative mortality, recurrence, reoperation, or
readmission rates. Other comparative cohorts have recently
reported no significant differences in terms of intraoperative
blood loss and LHS,6–9 as well as similar rates of readmission
and 30-day mortality.5,12
It has been frequently suggested that LDP has similar or
even superior oncologic outcomes compared to the open tech-
nique, such as rates of R0 resections and survival; however,
most of these studies are relatively small cohorts (<30 pa-
tients), they are often composed of nonhomogeneous samples
in terms of patient and tumor characteristics, and assess only
2- or 3-year survival rates.5,6,10,11,13,16,28,29 A recent study
shows that LDP for pancreatic adenocarcinoma does not com-
promise perioperative oncologic outcomes, but disease-
specific and overall survival data are lacking.12 In contrast,
our study is composed of 171 patients, all of whom were
diagnosed with PNETs and 5-year survival rates are assessed.
In analyzing oncologic outcomes between the two techniques,
it is also crucial to note that we had no statistically significant
differences in pathology between patients undergoing LDP vs.
ODP. In contrast, in many similar series, the pathological char-
acteristics between the two groups were significantly differ-
ent. For example, the minimally invasive group had signifi-
cantly smaller, lower grade tumors with less lymphovascular
invasion, fewer regional nodal metastases, more well-
differentiated tumors and lower stages of disease.5,12,16 Such
relevant differences in pathology constitute the main reasons
why recent comparative studies debate existing findings on
the oncologic equivalency of the two techniques.6,31–33
The overall survival rate of the PNET patients in our cohort
(90 %) is similar to other reports, where survival ranges be-
tween 65 and 90 % and was not significantly different be-
tween the LDP and ODP groups.27,34 Five-year survival rates
were similar using the WHO and ENETS-TNM classification
systems and was not influenced by type of resection—LDP
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vs. ODP. Nine patients with a WDCa and four patients with a
PDCa underwent R0 LDP without postoperative morbidity or
mortality at 5 years. Only one of these patients developed a
tumor recurrence at 21 months from surgery and was alive at
the conclusion of study follow-up, at 8 years from surgery.
Overall, three patients in the LDP group (4 %) developed a
recurrence after R0 resection. Additionally, three patients in
the LDP group—two of whom had WDTs and one with
PDCa—developed liver metastases, which were treated with
chemotherapy, and two of these patients were alive at the
conclusion of study follow-up.
Along with the classification and staging of PNETs, we
have examined pathologic characteristics that predicted poor
survival. Using univariate analysis, we found that tumors
>3 cm in diameter, high-grade tumors (G3), as well as positive
resection margins predicted poor survival. Consistent with
other data published,27,35 we found that WDCa, PDCa, and
TNM stages 3 and 4 were also statistically associated with
poor survival. On multivariable analysis, when controlling
for demographics and clinicopathologic characteristics, tumor
size >3 cm in diameter no longer correlated with poor surviv-
al; however, the remaining statistically significant factors on
univariate analysis all maintained their significant association
with poor survival. Interestingly, we found that 30-day read-
mission was a predictor of poor survival on multivariable
analysis.
Although questions have been raised concerning the cost of
the laparoscopic approach, large studies comparing direct
costs after LDP vs. ODP are scarce. Therefore, the economic
advantages of laparoscopic pancreatectomy are not settled.
Comparative small-sized trials report similar total direct costs
between LDP and ODP,8,36 but in contrast, a recent study
shows that the laparoscopic approach is associated with extra
cost.15 We demonstrated that LDP in comparison to ODP is
cost-neutral. Although the total direct costs, including nursing,
pharmacy, laboratory, and radiology costs were lower in the
LDP than the ODP group, these were not statistically signifi-
cant. Due to much higher supply expenses, median OR costs
were higher for the laparoscopic group than the open ap-
proach, but still not significantly so.
As with any retrospective review, this study has several
limitations. Although there were no statistically significant
differences in pathologic characteristics between the two
groups, smaller- and lower-grade PNETs without locoregional
or distant metastases were selected for the laparoscopic ap-
proach. As a result, there are relatively more malignant tumors
in the ODP group, though this is consistent with other
reports.5,25 We additionally acknowledge the relative difficul-
ty of comparing data in patients undergoing distal pancreatec-
tomy, given that multiple factors may play into the decision to
use the open or the laparoscopic approach. Lastly, our study
population is defined by the demographics seen at our institu-
tion, a high-volume academic center with experienced
pancreatic surgeons, and therefore results may be less appli-
cable at other institutions.
Conclusion
We conducted this study to address the current significant
controversy over the surgical outcomes of LDP vs. ODP as
treatment for pancreatic cancer. Based on our research, LDP
for PNETs presents similar long-term oncologic out-
comes as compared to ODP, providing reduced overall
morbidity in terms of postoperative complications without
compromising survival. Advanced WHO classification and
TNM stage, as well as positive resection margins, advanced
tumor grade, and 30-day readmission are predictors of poor
survival for PNET patients. Additionally, LDP is cost-neutral
as opposed to the open approach and yields shorter hospital
stays, less postoperative pain, better cosmetic results, and
faster postoperative recovery. Larger prospective controlled
trials are needed to further validate the advantages of LDP in
well-selected groups of patients.
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Commons Attribution License which permits any use, distribution, and
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